KCS Wealth Advisory’s Gilead Sciences GILD Stock Holding History

KCS Wealth Advisory’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,669	Closed	-$200K	–	145
2020 Q1	$200K	Buy	+2,669	New	+$184K	0.2%	131
2019 Q4	–	Sell	-3,098	Closed	-$196K	–	236
2019 Q3	$196K	Sell	3,098 -831	-21%	-$54.3K	0.14%	147
2019 Q2	$265K	Sell	3,929 -26	-0.7%	-$1.71K	0.21%	130
2019 Q1	$257K	Buy	3,955 +250	+7%	+$16.6K	0.22%	126
2018 Q4	$232K	Buy	+3,705	New	+$259K	0.24%	133
2018 Q3	–	Sell	-2,871	Closed	-$203K	–	151
2018 Q2	$203K	Sell	2,871 -215	-7%	-$15.2K	0.19%	146
2018 Q1	$233K	Buy	+3,086	New	+$245K	0.21%	144

Other funds holding GILD

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

KCS Wealth Advisory's GILD Position: Q2 2020 in Review

KCS Wealth Advisory sold out of Gilead Sciences (GILD) in Q2 2020, closing a stake of 2,669 shares — an estimated $200K sold.

KCS Wealth Advisory first reported a position in GILD in Q1 2018 and held it in 7 quarters. The position peaked at $265K in Q2 2019. 1,625 funds tracked by Wall St. Rank hold GILD as of Q2 2020.

KCS Wealth Advisory reported no remaining Gilead Sciences position as of Q2 2020 after selling out during the quarter.
KCS Wealth Advisory sold 2,669 Gilead Sciences shares in Q2 2020, an estimated $200K.
KCS Wealth Advisory first reported a position in Gilead Sciences in Q1 2018 and held it in 7 quarters.
KCS Wealth Advisory's Gilead Sciences position peaked at $265K in Q2 2019.
1,625 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2020.

Based on KCS Wealth Advisory's 13F filing for Q2 2020, filed 16 Jul 2020.